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In recent years, the relationship between inflammation and thrombosis has been deeply investigated and it is now
clear that immune and coagulation systems are functionally interconnected.
Inflammation-induced thrombosis is by now considered a feature not only of autoimmune rheumatic diseases, but
also of systemic vasculitides such as Behçet’s syndrome, ANCA-associated vasculitis or giant cells arteritis, especially
during active disease.
These findings have important consequences in terms of management and treatment. Indeed, Behçet’syndrome
requires immunosuppressive agents for vascular involvement rather than anticoagulation or antiplatelet therapy, and it
is conceivable that also in ANCA-associated vasculitis or large vessel-vasculitis an aggressive anti-inflammatory
treatment during active disease could reduce the risk of thrombotic events in early stages.
In this review we discuss thrombosis in vasculitides, especially in Behçet’s syndrome, ANCA-associated vasculitis and
large-vessel vasculitis, and provide pathogenetic and clinical clues for the different specialists involved in the care of
these patients.
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The relationship between inflammation and thrombosis is
not a recent concept [1], but it has been largely investigated
only in recent years [2]. Nowadays inflammation-induced
thrombosis is considered to be a feature of systemic auto-
immune diseases such as Systemic Lupus Erythematosus
(SLE) [3], Rheumatoid Arthritis (RA) [4], or Sjögren Syn-
drome (SS) [5]. Moreover, both venous and arterial throm-
bosis represents a well known manifestation of Behçet
syndrome (BS) [6]; more recently accumulating data have
demonstrated a significant increase in thrombo-embolic
events both in ANCA-associated vasculitis (AAV) and
large-vessel vasculitis (LVV) [7], especially during active dis-
ease. These findings have important consequences in terms
of management and treatment; for example, BS requires* Correspondence: giacomaci@yahoo.it
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unless otherwise stated.immunosuppressive treatment rather than anticoagulation
for venous or arterial involvement [8], and perhaps one
might speculate that also in AAV or LVV an aggressive
anti-inflammatory treatment during active phases could
ameliorate vascular involvement especially in early stages.
Here we will highlight some of the main pathogenetic
and clinical aspects of thrombosis in systemic vasculitis,
and in particular in BS, AAV and LVV [Table 1].Search strategy and selection criteria for review
We searched Pubmed matching the key search terms
“thrombosis in vasculitis”, “Behçet and thrombosis”,
“ANCA-associated vasculitis and thrombosis”, “Large
vessel vasculitis and thrombosis”. Full texts, as well as
abstracts of published articles were reviewed. The search
was limited to papers published in English language, and
was conducted through December 2014.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of clinical and therapeutic features of thrombotic events in systemic vasculitis
Disorders District involvement and treatment Data based on References
Behçet’s
syndrome
Venous involvement - venous involvement is common
and makes up 75% of all vascular complications. Venous
thrombosis occurs more frequently in males with active
disease during the early years, sometimes at the onset
of disease, and tends to recur.
Large survey (387 pts) and
retrospective evaluation (2319 pts)
[6,38-41]
Arterial involvement - the most characteristic arterial
manifestations are aneurysms whereas arterial thrombosis
is less common. The coexistence of thrombosis and
aneurysms is a peculiar feature of Behçet.
Retrospective evaluations and expert experience [6,11,13,42-44]
Treatment - the management of vascular thrombosis is
based on immunosuppressants rather than anticoagulants.
Azathioprine and cyclosporine in association with low dose
corticosteroids are usually the first choice in the treatment of
deep vein thrombosis and superficial vein thrombosis, while
cyclophosphamide is the suggested treatment for arterial
involvement. In resistant cases anti-TNFα agents could
be considered.






Venous involvement - increased incidence of venous
thromboembolism, especially during active disease.
Multicentric randomized placebo-controlled trial
(180 pts), retroprospective analysis (up to 1130 pts)
and monocentric experience (19 pts)
[61,69-74]
Arterial involvement - increased incidence of arterial
involvement and particularly of cardiovascular events.
Two large retrospective studies (113 and
239 pts respectively)
[75-77]
Treatment - there are controversial data on the use
of statins, while there are no significant data on the
use of antiplatelet and/or anticoagulant therapy.
In vitro study, case reports [78-80]
Large-vessel
vasculitis
Venous involvement - increased risk of venous
thromboembolism, both deep vein thrombosis
and pulmonary embolism, in particular during
the first year after diagnosis. Similar data are
reported in polymyalgia rheumatica.
Large population-based study (909 pts) and
nationwide population study (535.538 individuals)
[87-90]
Arterial involvement - increased risk of cardiovascular
events, especially in giant cell arteritis.
Large cohort study (3500 pts) and retrospective
analysis (210 pts)
[91-100]
Treatment - the use of antiplatelet/anticoagulant therapy
is not effective for primary prophylaxis, whilst it could be
beneficial as combination therapy with corticosteroids in
established giant cell arteritis. In Takayasu disease the use of
antiplatelet treatment could be protective for ischemic events.
Cumulative meta-analysis (6 retrospective studies,
914 pts), monocentric retrospective evaluation
(48 pts), retrospective analysis (297 pts)
[101-104]
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Introduction
Behçet’s syndrome is a systemic vasculitis with a hetero-
geneous clinical phenotype [9], characterized by oral and
genital ulcerations, uveitis, skin lesions and vascular,
neurological and gastrointestinal involvement. Inter-
national diagnostic criteria for BS, first published in
2006 and recently revised [10], have included vascular
involvement as a diagnostic criterion. The term angio-
Behçet is used to define patients in whom large vessel le-
sions are the main feature. Both arterial (e.g. aneurysms)
and venous involvement (e.g. deep venous thrombosis)
can occur [11]. A peculiar feature of BS is the associ-
ation between venous and arterial damage; some authors
have reported that pulmonary artery aneurysms and per-
ipheral venous involvement coexist in up to 90% of the
patients [12].Pathogenesis of (athero)thrombosis in Behçet’s syndrome
The pathophysiology of thrombosis in Behçet’s syndrome
(BS) is not well known, but systemic inflammation seems
to play a major role whereas other thrombophilic factors
are less relevant [13]. However, it should be underlined
that inflammation and haemostasis are closely linked and
that the immune system plays a role in the thrombotic
process [14]; BS may thus be considered a model of
inflammation-related thrombosis [15].
a) Immune system
A generalized derangement of CD4+ lymphocytes,
monocytes and neutrophils and an overproduction of pro-
inflammatory cytokines related to Th1 cells, such as
interferon-gamma (IFNγ), tumor necrosis factor (TNF)α,
interleukin (IL)1, IL6, IL8 and IL12, have been observed in
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TNFα, also seem to be involved in the inflammatory
process, and so is IL21 which may promote Th1 and Th17
differentiation and Treg cells suppression [17]. This condi-
tion is able to self-renew, so amplifying the proinflamma-
tory environment and promoting a prothrombotic state.
Different mechanisms of inflammation may affect endothe-
lial cells; in particular, in BS anti-endothelial cell antibodies
(AECA) have been described as a possible link between im-
mune response and endothelial dysfunction [18,19].
b) Coagulation system
In BS, the coagulation system may promote inflamma-
tion and thrombosis through multiple factors such as
the tissue factor (TF) pathway, thrombin and the protein
C system along with an impaired fibrinolysis [13]. Endo-
thelial cell dysfunction, resulting from immunological
and inflammatory factors, seems to be a characteristic
feature of BS and plays a key role in the pathogenesis of
thrombotic manifestations. A decreased production of
nitric oxide (NO), a prominent marker of endothelial
dysfunction, was reported in some patients with active
BS [20], and interestingly a reduction in asymmetric
dimethylarginine, the endogenous inhibitor of NO syn-
thase, has also been observed [21]. Moreover, high levels
of other endothelial injury markers, such as circulating
von Willebrand factor [22] and thrombomodulin [23]
were found in patients with active BS. Increased serum
levels of vascular endothelial growth factor (VEGF), a
marker of angiogenesis, and of some adhesion molecules
such as intercellular adhesion molecule 1 and E-selectin,
produced by activated endothelial cells, were reported in
BS patients. These markers were increased particularly
during the active stage of the disease, thus underlying
the close relationship between endothelial cells, leuko-
cytes and autoimmune mechanisms [24]. Another adhe-
sion molecule, P selectin, was found to be elevated in
the plasma of BS patients. This molecule, located in the
Weibel-Palade bodies of endothelial cells and in the
granules of platelets and released into the plasma during
platelet activation, promotes inflammatory reactions by
facilitating leukocyte recruitment at the site of injury
[25]. Some studies have also reported signs of enhanced
platelet activation including higher concentrations of
platelet microparticles (MPs) in BS patients compared
with healthy controls [26]. Moreover, several studies
have reported high plasma levels of homocysteine in BS
patients with a history of thrombosis, especially in the
active phase of disease [27], while data are conflicting on
the possible correlation between homocysteine and
HLA-B51 [28]; endothelial function, tested by flow-
mediated dilatation of the brachial artery was found to
be significantly impaired in BS patients [29]. Differenthaemostatic factors have been investigated in BS with
discordant results. Controversial data were reported
about the role of some procoagulant factors, such as co-
agulation factor V G1691A (factor V Leiden mutation)
and prothrombin G20210A polymorphisms in BS, sug-
gesting that they might be an additional risk factor for
thrombosis in certain populations. Factor V Leiden mu-
tation is reported to be more prevalent in Turkish
[30,31], but not in Italian, Spanish and Israelian patients
[32-34]. Prothrombin gene mutation was not reported to
be relevant in several studies [35], but a meta-analysis
showed a significant association between the presence of
prothrombin G20210A mutation and thrombosis in BS,
when Turkish patients were excluded [33]. Instead, defi-
ciencies of natural anticoagulant proteins including pro-
tein C, protein S and antithrombin have not been
associated with thrombosis in BS patients [36]. High
levels of Lipoprotein(a) were found in BS patients and
might be involved in the pathogenesis of thrombosis by
impairing fibrinolysis [15]. Furthermore, high plasma
levels of thrombin-activable fibrinolysis inhibitor were
reported in BS patients which could result in a signifi-
cant reduction of clot lysis process [37].
Venous thrombosis in Behçet’s syndrome
Thrombosis is the most frequent vascular manifestation in
BS patients, its prevalence ranges from 14% to 39% and
venous involvement is characteristically more common
and makes up 75% of all vascular complications [38]. Ven-
ous thrombosis occurs more frequently in males with ac-
tive disease during the early years, sometimes at the onset
of disease, and tends to recur [39,40]. Deep vein throm-
bosis (DVT) and superficial vein thrombophlebitis (SVT)
of lower extremities are the typical manifestations, but
thrombosis may occur anywhere in the venous system and
the involvement of atypical sites such as hepatic veins, su-
perior and inferior vena cava and cerebral sinus veins are
also observed [6]. BS should be always considered in the
differential diagnosis of venous thrombosis in unusual
sites in young individuals.
In some studies SVT have been reported as the most
frequent lesions. It usually occurs in the lower limbs as
painful nodules similar to erythema nodosum, but in
some cases it may be a complication of venipuncture
reflecting a pathergy-like effect in the venous wall [41].
Arterial involvement in Behçet’s syndrome
Arterial involvement is present between in 1 to 7% of the
patients [6]. The most characteristic arterial manifestations
in BS patients are aneurysms whereas arterial thrombosis is
less common [11]. These complications may remain
asymptomatic or result in life- or organ-threatening infarc-
tions such as acute myocardial infarction, stroke, intestinal
infarction, intermittent claudication or gangrene of the
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thromboses sometimes coexist in the same patient and may
be associated with aneurysms [42,43]. Thus, the coexistence
of thrombosis and aneurysms is a peculiar feature of BS.
Overall, cardiac manifestations are rare in BS patients, with
a reported incidence between 1% and 6%, and are mainly
represented by intracardiac thrombosis and coronary artery
disease [44].
Treatment
Currently, the management of vascular thrombosis in BS
patients is based on immunosuppressive therapy to reduce
the inflammation of the vessel wall. Anti-inflammatory
treatments are able to promote a rapid and effective re-
gression of the vascular lesions, to prevent the extension
of thrombosis and its recurrence. The European League
Against Rheumatism (EULAR) recommendations suggest
immunosuppressive treatment with agents such as corti-
costeroids (CS), azathioprine (AZA), cyclophosphamide
(CYC) or cyclosporine A (CsA) [8].
AZA and CsA in association with low dose CS are usu-
ally the first choice in the treatment of DVT and SVT. In
some serious cases such as Budd-Chiari Syndrome or su-
perior and inferior vena cava thrombosis, treatment with
pulse CYC is suggested [45]. CYC is also the recommended
treatment in BS patients with arterial involvement.
Usually, anticoagulants alone are not recommended in
BS patients [8]. Actually, only for CNS venous throm-
bosis some authors suggest anticoagulation, with or
without corticosteroids [46,47]. The pathophysiology of
thrombosis in BS, where systemic inflammation pro-
motes the prothrombotic state leading to the formation of
a thrombus tightly adherent to the vessel wall with a low
rate of embolism [13], the discordant data on coagulation
abnormalities, the possibility of the coexistence of PAA
and thrombosis and the low efficacy of the anticoagulants
reported in several studies are the main reasons that sup-
port the treatment with immunosuppressive agents and
not with anticoagulants in BS patients. However, the role
of anticoagulants continues to be an open question.
Sometimes thrombosis in BS as well as other manifes-
tations are refractory to traditional immunosuppressive
therapy and tend to recur, so more effective therapeutic
options are required. According to the hypothesis that
inflammatory cells and proinflammatory cytokines, in-
cluding gamma-delta T cells (γδ T cells) and TNFα, play
a major role in the development of thrombosis [48], a
successful use of anti-TNFα agents, especially for uveitis,
neurological and gastrointestinal manifestations, has
been increasingly reported in BS patients [48].
Cases of angio-Behçet patients resistant or intolerant
to conventional immunosuppressive therapy successfully
treated with anti-TNFα agents have been increasingly re-
ported over the last years. However, the experience withanti-TNFα agents for major vessel involvement is limited
to case reports. An analysis of 369 BS patients treated
with anti-TNFα agents in 20 different countries has re-
cently been reported [49], but only few cases of treat-
ment with anti-TNFα agents in BS patients with vascular
complications have been described [50,13].
Interestingly, among conventional agents used in car-
diovascular diseases, only atorvastatin and lisinopril have
been investigated, with results showing a possible im-
provement in endothelial function in BS patients [51].
ANCA-associated vasculitis
Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associ-
ated vasculitis (AAV) comprises a group of disorders
characterized by necrotizing inflammation of small
vessels and the presence of ANCA directed to specific
antigens, particularly proteinase 3 (PR3-ANCA) and
myeloperoxidase (MPO-ANCA) [52]. The main clin-
ical entities within the AAV spectrum are Granuloma-
tosis with Polyangitiis (GPA, formerly Wegener’s
Granulomatosis), Microscopic Polyangitiis (MPA) and
Eosinophilic Granulomatosis with Polyangitiis (EGPA,
formerly Churg-Strauss syndrome) [53].
Pathogenesis of (athero)thrombosis in ANCA-associated
vasculitis
a) Immune system
Endothelial cell dysfunction is a feature of AAV and is
probably caused by the interaction between neutrophils
(activated by TNFα and ANCA) and endothelial cells,
with consequent massive oxidative stress finally leading
to atherothrombotic complications [54].
Recently, an additional mechanism of neutrophil acti-
vation has been described, termed NETosis; neutrophils
are able to release extracellular nucleic acids associated
with histones and granular proteins capable of entrap-
ping bacterial agents. These neutrophil extracellular
traps (NETs) have been also implicated in thrombotic
events and seem to be a potential bridge between auto-
immunity and coagulation. In particular, neutrophils
primed by ANCA degranulate and release NETs, which
in turn contain MPO and PR3, that act as autoantigens,
thus creating a self-amplyfing process [55]. In active
AAV, neutrophils release high levels of TF-expressing
NETs [56]; moreover NETs are able to promote throm-
bosis by inhibiting the TF pathway inhibitor and by
recruiting platelets [14]. Finally, an intriguing in vivo
model in which dendritic cells primed by NETs are able
to induce the production of ANCA in mice has been re-
cently proposed, thereby strengthening the role of NETs
in AAV [57].
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cluding thrombosis [58]. Neutrophil-derived MPs have
been recently demonstrated in active AAV [56]; they
contain inflammatory mediators such as platelet activat-
ing factor, adhesion molecules and MPO, suggesting that
they may activate and damage endothelial cells [59,60].
In vitro and in vivo models have shown also in AAV a
possible role of AECA in inducing endothelial cell dys-
function via an antibody-dependent cytotoxicity mech-
anism [18,19].
In EGPA, in addition to neutrophils, also eosinophils
seem to promote vascular injury via the release of pre-
formed granules during active disease. In particular eo-
sinophil cationic protein and membrane basic protein
can inhibit the activation of the protein C system and, at
the same time, induce platelets to produce platelet factor
4, able to impair heparin function. TF and eosinophil
peroxidase are also released by activated eosinophils; the
former activates factor X, while the latter induces endo-
thelial cells to express TF [61-63].
b) Coagulation system
Plasminogen has been described as an autoantigen in
PR3-ANCA patients, and its interaction with autoanti-
bodies directed towards complementary PR3, a recom-
binant protein translated from the antisense strand of
PR3 cDNA, is able to block its conversion to plasmin,
ultimately impairing fibrinolysis [64,65].
Boomsma et al. have shown that elevated levels of sol-
uble thrombomodulin and plasma endothelial protein C
receptor, which are markers of endothelial cell damage
were increased in GPA patients and partly correlated
with disease activity [66].
Patients with GPA have not been reported to have an
increased prevalence of thrombophilic factors such as
Factor V Leiden and prothrombin gene mutations, while
they were found to have an increased prevalence of
anticardiolipin antibodies (aCL), although no correlation
with thrombotic events was reported [67].
More recently a procoagulant state was reported in
non active AAV as well: endogenous thrombin potential
and Factor VIII were found to be increased in patients
in stable remission compared to healthy controls [68].
Venous thrombosis in ANCA-associated vasculitis
In recent years, evidence supporting an increased fre-
quency of venous thrombotic events in AAV has arisen.
The prevalence of venous thrombosis in AAV ranges be-
tween 5.8% and 30% [61]. Relevant data came from the
WGET trial (Wegener’s granulomatosis Etanercept
Trial) published in 2005 [69]; in this study 180 patients
with GPA followed for more than 2 years had an in-
crease incidence of venous thromboembolism (VTE),especially during active disease. Subsequent studies
[70-72] confirmed a high frequency of thrombotic events
among patients with AAV, especially during early and
active disease stages. In a recent Australian case series of
EGPA patients [73] an increased incidence of VTE (both
in typical and atypical sites) and pulmonary embolism
(PE) was reported. Very recently a retrospective study
conducted in a Tertiary Reference Center in Denmark
has confirmed that patients diagnosed as having GPA
have a significant risk of VTE both early and late during
the course of their follow-up (median 7.2 yrs) and are
hospitalized several times for PE and DVT [74].
Arterial involvement in ANCA-associated vasculitis
An increased frequency of arterial events in AAV has
been reported in the literature. The estimated preva-
lence of arterial involvement in AAV is between 3.1%
and 18.7% [75,76]. In a retrospective study, 113 patients
with AAV were compared with a matched population
with non-inflammatory chronic kidney disease, showing
a significant increase in cardiovascular events (CVE) in
the AAV group. Previous cardiovascular disease, dialysis
dependence, and smoking were the strongest predictors
of CVE. Of note, only 2 patients with EGPA were in-
cluded, while the majority were patients diagnosed as
GPA (n = 65) and Microscopic Polyangiitis (MPA, n = 46)
[75]. Another retrospective study was conducted using the
Danish National Hospital Register, on 293 patients with
GPA; an increased risk of acute myocardial infarction was
observed, in particular in men aged >50 yrs at the time of
diagnosis and with a cumulative dose of cyclophospha-
mide >36 grams. Interestingly, this GPA population had
an increased risk of CVE both in the early (within
5 years of diagnosis) and in the late (after 10 years of
diagnosis) phase of the disease, suggesting that not only
acute, but also chronic inflammation may be implicated
in this process [76].
In 2011 a prognostic tool to define the 5-year cardiovas-
cular risk was created for AAV patients based on data
from four European Vasculitis Study Group (EUVAS) tri-
als of WG and MPA considering a total population of 535
patients. The results indicated that almost 12% of newly
diagnosed GPA and 16% of MPA patients had presented
at least one CVE, defined as cardiovascular death, myocar-
dial infarction, coronary artery bypass graft/percutaneous
coronary intervention or stroke. Interestingly in this risk
algorithm, while an older age and the presence of diastolic
hypertension were associated with an increased incidence
of CVE, the positivity of PR3-ANCA was associated with a
lower cardiovascular risk [77].
Treatment
An in vitro model has demonstrated that simvastatin is
able to significantly inhibit neutrophil degranulation
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in clinical practice beyond cardiovascular protection, al-
though some cases of AAV induced by statins have been
reported [79,80]. Currently there are no significant data




Large vessel vasculitis (LVV) usually comprises Giant
Cell Arteritis (GCA) and Takayasu arteritis (TA) [52].
The histopathologic features of these two entities are
similar, whilst they substantially differ in the age range
of the affected patients, since TA usually affects young
women and GCA predominates in the elderly [52].
Pathogenesis of (athero)thrombosis in large vessel vasculitis
The pathogenesis of atherothrombotic events in these
inflammatory conditions is overlooked.
a) Immune system
As in BS and in AAV, even in LVV, and especially in
TA, a possible role of AECA in inducing endothelial
damage has been suggested [18,19].
More interestingly, one of the possible vascular com-
plications is the development of aneurysms as a conse-
quence of inflammatory damage. Vessel wall remodeling
in LVV starts from the adventitial layer, with an infiltrate
mainly consisting of Th1/Th17 lymphocytes activated by
resident dendritic cells [81], and macrophages producing
pro-inflammatory cytokines such as IL1β and IL6; mac-
rophages of adventitial and medial layers are responsible
for the production of growth factors, such as platelet-
derived growth factor and VEGF, which induce intimal
hyperplasia [81,82]. Interestingly the innate immunity
also contributes to vascular remodeling, via pentraxin 3
(an innate pattern recognition receptor), which accumu-
lates at the site of active remodeling both in GCA and
TA vessels [83,84].
b) Coagulation system
Inheritable thrombophilia does not seem to have any
role in GCA patients; a high prevalence of antiphospho-
lipid antibodies was observed, without any correlation
with vascular events [85]. High levels of homocysteine
were reported in a single study in patients with poly-
myalgia rheumatica (PMR) and GCA, probably related
to corticosteroid treatment [86].
Venous thrombosis in large vessel vasculitis
Venous thrombosis in LVV has been poorly investigated.
In GCA the incidence rate of venous involvement isestimated to be 13.3/1000/year for VTE and 8.5/1000/
year for DVT [87]. A recent population-based study has
tried to fill this gap; in a large cohort comprising 909 pa-
tients with GCA, an increased risk of VTE (both DVT and
PE) in particular during the first year after diagnosis has
been observed [87]. Interestingly, similar findings were re-
ported in a recent Swedish nationwide hospital-based
study in patients affected by PMR, a condition strictly re-
lated to GCA, who showed an increased incidence of PE.
Also in this population the risk was higher during the first
year after diagnosis, suggesting a possible role of inflam-
mation in the pathogenesis of the vascular events [88].
None of the traditional risk factors has been definitely
linked so far to an increased occurrence of venous events
in GCA; in two previous reports of small populations, a
role for aCL antibodies was hypothesized [89,90].
Arterial involvement in large vessel vasculitis
Interesting data about arterial involvement in LVV are
available. A recent cohort study evaluating nearly 3500
patients with GCA has reported an increased risk of
CVE, especially in the first month after the diagnosis;
the study was mainly limited by the source of data (pri-
mary care database) and the lack of data about temporal
artery biopsies [91].
The influence of the traditional cardiovascular risk fac-
tors in GCA is far from being established, however a
retrospective Spanish study has reported several risk fac-
tors for atherosclerosis at the time of diagnosis, and
among them, especially hypertension significantly en-
hances the risk of developing severe ischemic events [92].
Another Spanish study on 287 GCA patients reported
that stroke occurred in almost 3% of them, mostly
within 1 month of diagnosis; most of the patients were
male, smokers and with arterial hypertension, and per-
manent visual loss was the best predictor of stroke oc-
currence [93]. A recent population-based study has
confirmed these data, except for a higher incidence of
stroke (7%) [94].
An Italian study conducted by Salvarani et al. demon-
strated that the PlA2/A2 homozygosity of the GPIIIa gene
is associated with anterior ischemic optic neuritis in GCA
and could partly explain the reduced capacity of aspirin to
prevent cerebral events in this population [95]. Another
study by the same group [96] interestingly showed that, to-
gether with a history of arterial hypertension and previous
CVE, also low levels of acute phase reactants were associ-
ated with occurrence of cerebral accidents; this evidence is
not surprising, since the data published by Hernández-
Rodríguez and colleagues demonstrated that the angio-
genic properties of IL6 could compensate ischemic injury
in GCA patients [97]. Curiously, a recent retrospective
study on 245 patients with GCA has shown that the risk of
acute coronary syndromes in patients with GCA was
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cardiovascular risk factors, such as diabetes, were found to
be protective in the GCA population [98]. As previously
reported, GCA patients with coronary artery disease how-
ever demonstrated an increased risk of aortic aneurysm
and arterial thrombosis [99].
In a Korean retrospective study on Takayasu arteritis,
21 of 190 (11%) patients, almost all young (mean
age <40 years) female had presented a stroke [100]. In
this population, risk factors were comparable between
Takayasu-stroke and Takayasu non-stroke patients, while
transient monocular blindness (considered a warning bell
of cerebral events) occurred at low frequency.
Treatment
A recently published comprehensive meta-analysis has
clearly shown that in GCA the use of antiplatelet/anticoa-
gulation therapy is not effective for primary prophylaxis,
whilst it could be beneficial as combination therapy with
corticosteroids in established GCA, without an increased
risk of bleeding [101]. In TA the use of antiplatelet
treatment appears to have a protective effect against is-
chemic events, while neither anticoagulants, nor corti-
costeroids/immunosuppressants seem to be able to
prevent CVE [102].
A retrospective recent study has shown that patients
using statins were less likely to develop GCA compared
to patients not using them [103]. Interestingly, a recent
association study performed using the World Health
Organization database, has suggested that the occur-
rence of PMR could be correlated with statin use [104].
Others systemic vasculitis
Polyarteritis nodosa
Polyarteritis nodosa (PAN) is a multisystemic necrotiz-
ing vasculitis of medium-sized arteries, not associated
with glomerulonephritis, nor with ANCA positivity [52].
Few conflicting results about thrombotic events in PAN
exist; indeed one study on 285 PAN patients has reported
a much lower incidence of VTE compared to AAV pa-
tients [72], whilst a more recent Swedish population-based
study has suggested an increased risk of thrombotic events
[88]; of note, the latter study included subjects with differ-
ent autoimmune diseases observed from 1964 to 2008,
thus it is unclear whether or not patients with MPA were
included together with PAN patients. Finally, a certain re-
lation seems to exist between PAN and antiphospholipid
antibody syndrome, so complicating the scenario [105].
Henoch-Schönlein purpura
Henoch-Schönlein purpura (HSP) is a systemic vasculitis
of the small vessels mainly affecting children. Throm-
botic events are rare complications of HSP, and to date
only case reports are reported [106].Kawasaki disease
Kawasaki disease is a systemic vasculitis and represents
the most common cause of acquired heart disease in
childhood. Sometimes, despite appropriate treatment with
acetylsalicylic acid and intravenous immunoglobulins, cor-
onary aneurysms occur; the formation of a thrombus at
this level could lead to vascular occlusion and consequent
myocardial infarction [107].
Retroperitoneal fibrosis
Retroperitoneal fibrosis (RPF) is a rare fibroinflamma-
tory disorder characterized by the presence of a retroperi-
toneal mass, that could be associated with abdominal
aorta aneurysms and/or vasculitis of the thoracic aorta;
RPF could be primary or secondary, mainly to neoplastic
or infectious diseases. Venous thrombosis could be a pres-
entation symptom in RPF due to the compression of vas-
cular structures, in particular of the inferior vena cava and
iliac veins [108].Conclusions
The relationships between both innate and adaptive im-
munity and coagulation are becoming more evident and
nowadays it is quite clear that inflammation and throm-
bosis (both arterial and venous) are tightly related.
Moreover, inflammation-induced thrombosis is consid-
ered not only a feature of several autoimmune diseases,
such as SLE, RA or SS, but also of systemic vasculitis.
Among vasculitides, BS represents the model of throm-
bosis induced by inflammation, but more recently accumu-
lating data have also demonstrated a significant increase in
thrombo-embolic events in patients with both small and
large vessel vasculitis syndromes. In particular, EGPA,
GPA, and GCA have an increased incidence of both ven-
ous and arterial thrombotic events especially during the
early and active phases of disease.
These concepts have important consequences in terms
of management. Indeed, BS requires immunosuppressive
agents for venous or arterial involvement rather than
anticoagulation or antiplatelet therapy and one might
speculate that also in AAV or LVV an aggressive anti-
inflammatory treatment during the active phases could
improve vascular involvement especially in early stages.
Nowadays, conflicting data exist about the role of anti-
platelet/anticoagulant therapy in LVV, while their role in
AAV is obscure.
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